EECP Improves Outcome in Patients with Heart Failure 體外反搏治療有效改善心臟衰竭

Source From 資料來源 : https://pubmed.ncbi.nlm.nih.gov/16684494/

EECP Improves Outcome in Patients with Heart Failure

Balloon counterpulsation has gained widespread acceptance as a therapy for cardiogenic shock. However, over the past four decades a parallel method of noninvasive counterpulsation, enhanced external counterpulsation (EECP), has been defined and developed. Mechanisms of benefit for this technology continue to emerge and include enhanced coronary and other key target organ perfusion beds. Other mechanisms include angiogenesis and enhanced cellular metabolism. Beyond putative mechanisms there is ample evidence for improved and sustained outcomes in patients with and without left ventricular dysfunction. This evidence comes from long-term registry reports and randomized clinical trials. With respect to heart failure (HF), there is registry, pilot trial, and randomized clinical trial evidence of safety and efficacy. This paper summarizes some of the mechanisms and outcomes of EECP in HF patients and helps to elucidate the role of EECP in the management of patients with chronic HF.

「體外反搏治療心臟衰竭的機制和 證據 」

球囊反搏作為一種治療心源性休克的方法已被廣泛接受。然而,在過去的四十年中,非侵入性反搏方法:體外反搏治療(EECP)得到了定義和發展。該技術的獲益機制不斷湧現,包括增強冠狀動脈和其他主要目標器官的灌注床。其他機制包括血管生成和細胞代謝增強。除了推測的機制外,還有大量 證據 表明,有左心室功能障礙或無左心室功能障礙的患者都得到了改善和維持。這些 證據 來自長期登記報告和隨機臨床試驗。關於心臟衰竭(HF),有登記報告、試點試驗和隨機臨床試驗的安全性和有效性 證據 。本文總結了 EECP 在心臟衰竭患者中的一些機制和結果,並幫助闡明 EECP 在心臟衰竭患者中的作用。

×